How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

6,179 results for

Lymphadenopathy in HIV

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1621. Expanded Access Metreleptin Study

abnormalities (such as neutropenia and/or lymphadenopathy) Medical History and Concurrent Diseases Has been diagnosed with generalized lipodystrophy Has been diagnosed with HIV infection Has a clinically significant medical condition that could potentially affect the risk/benefit ratio for metreleptin treatment and/or the personal well-being of the patient, as judged by the primary treating physician Has known infectious liver disease Has known allergies to E. coli-derived proteins or hypersensitivity (...) the basis of the request for ongoing treatment under expanded access. Condition or disease Intervention/treatment Phase Familial Partial Lipodystrophy Drug: Metreleptin Phase 2 Detailed Description: Leptin is a naturally occurring hormone and an important regulator of energy homeostasis and other diverse physiological functions. Circulating levels of leptin closely correlate with the amount of adipose tissue present. Metreleptin, a recombinant analogue of human leptin, is a 147-amino acid polypeptide

2015 Clinical Trials

1622. Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

human chorionic gonadotrophin (Beta-hCG) pregnancy test result within 24 hours prior to the first dose of treatment and must (...) . Current or chronic hepatitis B or C infection, or known seropositivity for HIV. Note: Patients with previous history of Hepatitis B (who have cleared the infection and have natural immunity, i.e. Hep B core antibody positive cases) are excluded if prophylaxis against Hep B reactivation with antiviral agents (such as entecavir) is recommended, after consultation with gastroenterologist/hepatologist or infectious disease team. Patient is pregnant or breast-feeding. Concurrent use of investigational

2015 Clinical Trials

1623. Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

(viral, bacterial, and fungal) are not eligible. Current or chronic hepatitis B or C infection, or known seropositivity for Human Immunodeficiency Virus (HIV). Patient is pregnant or breast-feeding. Concurrent use of investigational therapeutic agent. Malabsorption syndrome or other condition that precludes enteral route of administration. Concomitant use of warfarin or other Vitamin K antagonists. Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor. Other severe acute or chronic (...) have adequate renal and hepatic function: -- Total bilirubin human chorionic gonadotrophin (Beta-hCG) pregnancy test result within 24 hours prior

2015 Clinical Trials

1624. Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

status of ≤ 2 he/she may be enrolled provided that other eligibility criteria are met Ongoing or active infection of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 3 Known history of human immunodeficiency virus (HIV) infection Acute or chronic hepatitis B (HBV) or hepatitis C (HCV) infection requiring concomitant treatment prohibited by this protocol (i.e.immunosuppressive therapy) History or concurrent condition of interstitial lung disease of any severity and/or severely impaired (...) for additonal information Responsible Party: Bayer ClinicalTrials.gov Identifier: Other Study ID Numbers: 17120 First Posted: May 27, 2015 Last Update Posted: October 2, 2017 Last Verified: September 2017 Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, Mantle-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin

2015 Clinical Trials

1625. A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma

coagulation); had received live vaccine within 4 weeks prior to study entry; with other malignancies ; or central nervous system (CNS) lymphoma, AIDS-related lymphoma; or active opportunistic infection, a serious nonmalignant disease; seropositive for HCV antibody, or HIV antibody, or hepatitis B virus surface antigen (HBsAg). HBc antibody seropositive, but HBV DNA and HBsAg negative patients may participle following consultation with a hepatitis expert regarding monitoring and use of HBV antiviral (...) (MabThera®), as well as the presence of human anti-chimeric antibodies (HACA). Condition or disease Intervention/treatment Phase B-cell Non Hodgkin's Lymphoma Drug: SCT400 Drug: Rituximab Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 80 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase II, Multi-center, Randomized

2015 Clinical Trials

1626. Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

test performed within 48 hours before infusion, because of the potentially dangerous effects on the fetus; There is no obvious dysfunctions in heart , liver and kidney, and the functions of vital organs are normal; Serology: (1) Seronegative for HIV antibody; (2) Seronegative for hepatitis B virus (HBV) and hepatitis C virus (HCV). Hematology: (1) Absolute neutrophil count ≥ 1000/mm3 without support of filgrastim; (2) Platelet count ≥ 50,000/mm3; (3) Hemoglobin > 8.0g/dL; (4) lymphocyte count (...) potential who are pregnant or breastfeeding; Active systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system; Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease); Concurrent opportunistic infections; Concurrent Systemic steroid therapy; History of severe immediate hypersensitivity reaction to any of the agents used in this study; Patients with central nervous system (CNS) metastases or symptomatic

2015 Clinical Trials

1627. Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

Female patients who are pregnant or breast-feeding Known diagnosis of HIV Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol. Known cerebral or meningeal disease (HL or any other etiology), including signs or symptoms of PML Symptomatic neurologic disease compromising normal activities (...) ClinicalTrials.gov Identifier: Other Study ID Numbers: AGMT_ALCL1 First Posted: June 4, 2015 Last Update Posted: January 10, 2019 Last Verified: January 2019 Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, Non-Hodgkin Lymphoma, Large-Cell, Anaplastic Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, T-Cell Imatinib Mesylate Antibodies, Monoclonal Antineoplastic Agents Protein Kinase

2015 Clinical Trials

1628. Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients

prior to being registered for protocol therapy. Exclusion Criteria: Active infectious disease uncontrolled by antibiotics. Partially treated induction patients (i.e. day 14 non responding patients). Inability to receive high dose salvage chemotherapy. Patient with known positive HIV serology at screening. Female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study. Evidence of ongoing cardiac dysrhythmias of NCI Common Toxicity Criteria (...) 2018 Additional relevant MeSH terms: Layout table for MeSH terms Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Leukemia, Lymphoid Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Mitoxantrone Cytarabine Antineoplastic Agents Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular

2015 Clinical Trials

1629. The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department

Virus Infections Virus Diseases Leukocyte Disorders Hematologic Diseases Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases (...) . ClinicalTrials.gov Identifier: NCT02463669 Recruitment Status : Recruiting First Posted : June 4, 2015 Last Update Posted : March 5, 2019 See Sponsor: Jewish General Hospital Information provided by (Responsible Party): Laurie Robichaud, Jewish General Hospital Study Details Study Description Go to Brief Summary: The purpose of this study is to determine if splenomegaly on point-of-care ultrasound (POCUS) is an accurate and user-friendly surrogate to the heterophile antibody test and Epstein-Barr Virus (EBV

2015 Clinical Trials

1630. A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

history of human immunodeficiency virus (HIV) or Active hepatitis C Virus or Active Hepatitis B Virus infection or any uncontrolled Active systemic infection requiring intravenous antibiotics Any Life-threatening illness, Medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules or lenalidomide tablets, or put the study outcomes at undue risk Known hypersensitivity (...) subjects of childbearing potential must: Understand that the study medication is expected to have a teratogenic effect Agree to use, and be able to comply with, highly effective contraception without interruption, 4 weeks Before start study drug, throughout study drug therapy (including dose interruptions) and for 12 months after the end of study drug therapy, even if she has amenorrhoea Women of childbearing potential must have a negative serum (beta-human ionic gonadotropin or urine pregnancy test

2015 Clinical Trials

1631. Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin

) For patients aged 70 years old and more, a Mini Nutritional Assessment (MNA) ≥ 17 A minimum life expectancy of 3 months Negative Human Immunodeficiency Virus, Hepatitis B (HB) Virus (anti-HB c negativity) and Hepatitis C Virus serologies tests ≤ 30 days before inclusion (except after vaccination) Having previously signed a written informed consent The patient must be covered by a social security system, if applicable Men patient must agree to use an adequate method of contraception during the study (...) Product: No Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Hodgkin Disease Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Doxorubicin Liposomal doxorubicin Prednisone Bendamustine Hydrochloride Vinblastine Antibiotics, Antineoplastic Antineoplastic Agents Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti

2015 Clinical Trials

1632. Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma

or other serious uncontrolled medical conditions Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) Patient has baseline neuropathy of > grade 2 Patient has known hypersensitivity to any of the excipients of ribociclib Patient has a known history of human immunodeficiency virus (HIV) infection (testing (...) : patients with any grade of alopecia are allowed to enter the study) Patient with a Child-Pugh score B or C (for cirrhosis patients only) Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods

2015 Clinical Trials

1633. Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

potential should use two appropriate methods of contraception during the study Written informed consent Exclusion Criteria: Not all of the above inclusion criteria are met. Prior chemotherapy within 4 weeks or radiotherapy within 6 weeks Corticosteroids during last 28 days except chronic administration of prednisolone at a dose of < 20mg/day for indications other than lymphomas Evidence of CNS involvement by lymphomas Active HBV/HCV infections, known HIV infection Prior diagnosis of cancers within 5 (...) ClinicalTrials.gov Identifier: Other Study ID Numbers: LY14-09 First Posted: May 5, 2015 Last Update Posted: June 21, 2018 Last Verified: June 2018 Keywords provided by Dae Seog Heo, Seoul National University Hospital: Marginal zone B-cell lymphoma bendamustine plus rituximab Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, B-Cell Lymphoma, B-Cell, Marginal Zone Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders

2015 Clinical Trials

1634. Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

nervous system involvement, meningeal or parenchymal. Patients with CNS disease at initial presentation and who are in a CNS CR at the time of relapse are eligible. MRI scanning and / or lumbar puncture should be performed if there is clinical suspicion of active CNS disease. Major surgery performed within 10 days of randomization. Known history of human immunodeficiency virus (HIV), active Hepatitis C Virus infection, active Hepatitis B Virus infection or any uncontrolled active systemic infection (...) for 12 months (1 year) after the last dose of study drug. Women of childbearing potential must have a pregnancy test taken (either by serum beta-human chorionic gonadotropin [B-hCG]) or urine) and proven negative within 14 days prior to randomization. Women who are pregnant or breastfeeding are ineligible for this study. Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial

2015 Clinical Trials

1635. Study of Treatment Response on IgG4 Related Disease (IgG4RD)

), sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions; elevated serum IgG4 (>1.35 g/L); histopathologic features of fibrosis and/or lymphocytic and polyclonal plasma cell infiltration (and IgG4+ plasma cells on immunohistology when performed). Patients fulfill 1)+2)+3) are diagnosed as definite IgD4RD, 1)+2): possible IgG4RD (...) ; 1)+3): probable IgG4RD; exclusion of other diseases. Exclusion Criteria: Patients will not be included if meets any of the following criteria: Patients who were diagnosed as other autoimmune diseases; Patients who were diagnosed as malignant diseases; Pregnant and lactating women; Active infection: HIV, HCV, HBV, TB; Serious organ function failure, expected life time less than 6 months. Presenting with Mikulicz disease without other manifestations. Contacts and Locations Go to Information from

2015 Clinical Trials

1636. BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

, chronic or persistent infection that might worsen with immunosuppressive treatment; positive for HIV or tuberculosis (TB) at Screening. Patients who are confirmed positive and those who have active infections are excluded from the trial participation. Patients with serological evidence of HBV infection. Patients seropositive because of HBV vaccine are eligible. HBV positive patients may participate following consultation with a hepatitis expert regarding monitoring and use of HBV antiviral therapy (...) , Follicular Lymphoma, Non-Hodgkin Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Rituximab Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents

2015 Clinical Trials

1637. A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

to starting study drugs. Subjects must have recovered from any effects of recent surgery or therapy that might confound the safety evaluation of study drug. Prior treatment with CC-122 History of severe allergic or anaphylactic reactions to humanized monoclonal antibodies. a. Allergic to any excipients in obinutuzumab. Known human immunodeficiency virus (HIV) infection. Known chronic active hepatitis B or C virus (HBV, HCV) infection. Subjects who are seropositive due to HBV vaccination are eligible (...) of the cervix or breast) unless the subject has been free of the disease for ≥ 1 year prior to starting study drugs. Prior immunization with live virus vaccines (within 3 months prior to starting study drug) or anticipated immunization with live virus vaccines during the duration of the study. Pregnant or nursing females. Unwilling or unable to comply with the protocol, in the opinion of the Investigator. Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2015 Clinical Trials

1638. Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

institutional guidelines are acceptable. Known human immunodeficiency virus (HIV) infection (pre-study testing not required). Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, study participation, follow up, or interpretation of study research. Patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome, or other inherited bone marrow failure syndromes are not eligible. Patients who in the opinion of the investigator may (...) toxicity) are not eligible. Patients with clinically significant prior allergies to PEG-asparaginase are eligible if Erwinia L-asparaginase can be substituted. Pregnancy and breast feeding: patients who are pregnant or breast-feeding are not eligible for this study as there is as yet no available information regarding human fetal or teratogenic toxicities. Negative pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless

2015 Clinical Trials

1639. Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy

resided in Canada for at least 30 years. Main Exclusion Criteria: Have received Varicella Zoster Vaccine vaccine or known allergies to the Varicella Zoster Vaccine vaccine or its excipients including neomycin and gelatin Primary and acquired immunodeficiency states due to conditions such as: acute and chronic leukemias, lymphoma, other conditions affecting the bone marrow or lymphatic system, immunosuppression due to HIV/AIDS, cellular immune deficiencies. Current use of non-topical antiviral therapy (...) : Innovaderm Research Inc. Collaborator: Merck Sharp & Dohme Corp. Information provided by (Responsible Party): Innovaderm Research Inc. Study Details Study Description Go to Brief Summary: This study will evaluate the ability of the vaccine to produce antibodies against herpes zoster virus (shingles) and safety of vaccination with Varicella Zoster Vaccine in patients with moderate to severe psoriasis who will initiate biologic therapy 4 to 6 weeks after vaccination. Varicella Zoster Vaccine

2015 Clinical Trials

1640. Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

of subjects for pregnancy after the last dose of study drug or chemotherapy. Exclusion Criteria: Active clinically serious infection > Grade 2. Serious non-healing wound, ulcer, or bone fracture. Patient has known brain metastases. Patient has with myelodysplasia, polycythemia vera, idiopathic thrombocythemia, myelofibrosis, or acute leukemia. Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements. Patient has known active infection with HIV (...) Center ClinicalTrials.gov Identifier: Other Study ID Numbers: WG2014035 First Posted: April 3, 2015 Last Update Posted: June 27, 2017 Last Verified: December 2015 Additional relevant MeSH terms: Layout table for MeSH terms Lymphoma Lymphoma, Non-Hodgkin Hodgkin Disease Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Carboplatin Rituximab Pembrolizumab Etoposide Etoposide phosphate Ifosfamide Isophosphamide

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>